---
title: "Barzolvolimab (CDX-0159) in Chronic spontaneous urticaria: Systemic corticosteroids for acute exacerbations"
description: "Formulary evidence on Barzolvolimab (CDX-0159) in Chronic spontaneous urticaria: Systemic corticosteroids for acute exacerbations. Topics: International guideline: short rescue course for acute exacerbations and against long-term use; International guideline: prednisone-equivalent dose, licensing, and use in children; Corticosteroid use, adverse events, and health care resource use in a Novartis-funded US claims study; Corticosteroids as the most prescribed treatment in a US claims cohort with diagnosed CSU. 4 evidence topics quoted from 4 sources."
canonical: "https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/product-information-and-disease-description/systemic-corticosteroids-for-acute-exacerbations"
published: "2026-11-18T22:38:31-05:00"
modified: "2026-11-18T22:38:31-05:00"
---

# Barzolvolimab (CDX-0159) in Chronic spontaneous urticaria: Systemic corticosteroids for acute exacerbations

<a id="heading-2.2.2.1.6"></a>

## 2.2.2.1.6 Systemic Corticosteroids for Acute Exacerbations

<a id="topic-2.2.2.1.6-1"></a>

### International guideline: short rescue course for acute exacerbations and against long-term use

> “We recommend against the long‐term use of systemic glucocorticosteroids or depot preparations in CU.”
> “We suggest considering a short course of rescue systemic glucocorticosteroids in patients with an acute exacerbation of CU.”
> “For acute urticaria and acute exacerbations of CSU, a short course of oral corticosteroids, that is, treatment of a maximum of up to 10 days, may, however, be helpful to reduce disease duration/activity”
> “Nevertheless, well‐designed randomized clinical trials are lacking.”

Source: [Zuberbier et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13466004/)

<a id="topic-2.2.2.1.6-2"></a>

### International guideline: prednisone-equivalent dose, licensing, and use in children

> “If systemic corticosteroids are used, doses between 20–50 mg/day of prednisone equivalent are needed (dose is appropriate for adults and not children).”
> “Because such high doses will have side effects over the long term, we strongly recommend against the prolonged use of corticosteroids.”
> “Depending on the country it must be noted that steroids are also not licensed for CU”
> “a short course of corticosteroids as advised in the algorithm should be used only as a very restricted measure in children.”

Source: [Zuberbier et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13466004/)

<a id="topic-2.2.2.1.6-3"></a>

### Corticosteroid use, adverse events, and health care resource use in a Novartis-funded US claims study

> “This retrospective cohort study used data from the US HealthVerity claims database of adults with diagnosed CSU (January 2016–March 2023).”
> “Of 200,298 patients, corticosteroids were the most prescribed treatment (78.3% all; 68.2% systemic) following CSU diagnosis, excluding over-the-counter medication and antihistamines.”
> “The ten most common AEs occurring after systemic corticosteroid initiation (hypertension, lipid disorders, anxiety, obesity, fatigue, depression, diabetes, insomnia, cataracts, and gastritis) occurred in higher proportions of all corticosteroid user types versus non-users.”
> “The proportion of patients experiencing AEs generally increased with longer duration of corticosteroid use.”
> “More frequent HCRU was generally observed after the first systemic corticosteroid prescription and with increasing duration of corticosteroid use.”
> “This study and article publication, including the journal’s Rapid Service Fee, was funded by Novartis Pharmaceuticals Corporation”

Source: [Yosipovitch et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13493736/)

<a id="topic-2.2.2.1.6-4"></a>

### Corticosteroids as the most prescribed treatment in a US claims cohort with diagnosed CSU

> “Adults with a record of CSU diagnosis within the US HealthVerity claims database were eligible.”
> “Corticosteroids were the most prescribed treatment during follow-up among the 166,195 patients prescribed at least 1 treatment (94.3%).”

Source: [Riedl et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/39694087/)

Additional sources: [AAAAI/ACAAI JTF Chronic Urticaria Guideline Panel (2026)](https://college.acaai.org/wp-content/uploads/2026/06/JTF-CU_guideline-2026-06-01-For-Distribution.pdf)

## Related pages
- [Barzolvolimab (CDX-0159): Chronic spontaneous urticaria](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria) · [Markdown](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria.md)
- [Barzolvolimab (CDX-0159) in Chronic spontaneous urticaria: Terms and abbreviations](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/terms-and-abbreviations.md)
- [Barzolvolimab (CDX-0159): Chronic spontaneous urticaria](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/executive-summary) · [Markdown](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/executive-summary.md)
- [Barzolvolimab (CDX-0159) in Chronic spontaneous urticaria: Product information and disease description](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/product-information-and-disease-description.md)
- [Barzolvolimab (CDX-0159) in Chronic spontaneous urticaria: Clinical evidence](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/clinical-evidence.md)
- [Barzolvolimab (CDX-0159) in Chronic spontaneous urticaria: Economic information and modeling report](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/economics) · [Markdown](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/economics.md)
- [Barzolvolimab (CDX-0159) in Chronic spontaneous urticaria: References](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/references) · [Markdown](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/references.md)
